🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Chang‐Ching Lin

ORCID: 0000-0001-6659-5543

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer”.

A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer

EBioMedicine(2025)10.1016/j.ebiom.2025.105828

N/A

0.404DataRank · unranked

7 citations

Rosario Chica-Parrado, Caroline Weipert, Todd C. Knepper, Emily Podany, Fabiana Napolitano +21 more

Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer

Nature Communications(2020)10.1038/s41467-020-19291-x

N/A

0DataRank · unranked

52 citations

Ángel Guerrero‐Zotano, Alberto Servetto, Dhivya R. Sudhan, Chang‐Ching Lin, Luigi Formisano +11 more

Corrigendum to “Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer” [Canc. Lett. 438 (2018, Dec 1) 165–173]

Cancer Letters(2020)10.1016/j.canlet.2020.01.013

N/A

0DataRank · unranked

2 citations

Miao‐Chia Lo, Rebecca Moody, Hui Jiang, Ramdane Harouaka, Nicholas Stevers +5 more

Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity

Cancer Cell(2021)10.1016/j.ccell.2021.06.001

N/A

0DataRank · unranked

103 citations

Benjamin P. Brown, Jens Meiler, Arnaldo Marín, Harikrishna Sekar Jayanthan, Dan Ye +13 more